Diamyd Medical precision medicine patent for prevention and treatment of autoimmune diabetes to be granted in Mexico

The patent set to be granted in Mexico will be valid until 2038, providing key protection for the use of a GAD autoantigen in treating or preventing autoimmune diabetes in individuals carrying the HLA DR3-DQ2 gene. GAD is the active component of the antigen-specific immunotherapy Diamyd[®], which is currently being evaluated in the confirmatory Phase 3 trial, DIAGNODE-3.HLA DR3-DQ2, a genetic variant strongly associated with autoimmunity against GAD, is one of the most common genetic risk factors for Type 1 Diabetes, with up to 40 % of individuals with the disease carrying this gene. A